Ku Lang Chang, MD
Family Medicine · Morehead City, NCNPI 1063432318
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,452 of the $9,641 with a category attached, or 98.0%. Boehringer Ingelheim accounts for 98.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $9,452 and has fallen 99.8% since, to $19 in 2025. Among family medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $1377.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$9K
- AstraZeneca$85
- Novo Nordisk$50
- Tandem Diabetes Care, Inc.$32
- Sequel Med Tech, LLC$19
- Cequr Corporation$4
Across 26 payments — averaging $5525.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$75K
- Modernatx, Inc.$65K
- Ionis Pharmaceuticals, Inc.$3K
What the payments were for
- Speaking & faculty fees$9,45298%
- Food & beverage$1892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $9,452 |
| AstraZeneca | 1 | $85 |
| Novo Nordisk | 1 | $50 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Sequel Med Tech, LLC | 1 | $19 |
| Cequr Corporation | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPIRIVA$9,452
How this compares
$9,641 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 163 | $235,276 |
| MounjaroTirzepatide | 38 | $63,753 |
| JardianceEmpagliflozin | 43 | $56,449 |
| TrulicityDulaglutide | 33 | $54,148 |
| FarxigaDapagliflozin Propanediol | 26 | $26,083 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $15,391 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $12,231 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $7,742 |
| SynthroidLevothyroxine Sodium | 95 | $7,009 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $6,018 |
| NexletolBempedoic Acid | 12 | $4,604 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $4,054 |
| Novolog FlexpenInsulin Aspart | 14 | $2,878 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 17 | $1,757 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $50 | $235,276163 claims |
| Boehringer IngelheimJardiance | $9,452 | $56,44943 claims |
| AstraZenecaFarxiga | $85 | $26,08326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Morehead City
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.